Imatinib Sandoz 100 mg Slovakia - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

imatinib sandoz 100 mg

sandoz pharmaceuticals d.d., slovinsko - imatinib - 44 - cytostatica

Imatinib Sandoz 400 mg Slovakia - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

imatinib sandoz 400 mg

sandoz pharmaceuticals d.d., slovinsko - imatinib - 44 - cytostatica

NIBIX 400 mg Slovakia - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

nibix 400 mg

adamed pharma s.a., poľsko - imatinib - 44 - cytostatica

NIBIX 100 mg Slovakia - slovakisk - ŠÚKL (Štátny ústav pre kontrolu liečiv)

nibix 100 mg

adamed pharma s.a., poľsko - imatinib - 44 - cytostatica

Tecartus Den europeiske union - slovakisk - EMA (European Medicines Agency)

tecartus

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfóm, mantle-cell - antineoplastické činidlá - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Scemblix Den europeiske union - slovakisk - EMA (European Medicines Agency)

scemblix

novartis europharm limited - asciminib hydrochloride - leukémia, myelogénna, chronická, bcr-abl pozitívna - antineoplastické činidlá - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.